7 results about "Eukaryote" patented technology

The invention relates to application of DNA polymerase in long-fragment precise gene editing and construction in a plurality of human-derived cell lines. The invention belongs to the technical field of biological medicine. A novel gene editing system MMEJ-Pol theta is created by applying DNA polymerase Pol theta and a key functional structure domain, the accuracy, safety and editing efficiency of long-fragment gene editing in a eukaryotic genome are remarkably improved through a micro homologous end linking method, and an effective tool is provided for transformation application of the gene editing system in gene therapy and cell therapy.

The application discloses a pig IZUMO2 eukaryotic protein and a preparation method and application of a monoclonal antibody of the pig IZUMO2 eukaryotic protein. The full-length sequence of pig IZUMO2 nucleotide CDS is verified, a research method for removing the transmembrane structure of the pig IZUMO2 nucleotide CDS and only expressing the extramembrane sequence of the pig IZUMO2 nucleotide CDS in eukaryotes is designed, and the IZUMO2 protein is expressed and secreted by CHO-K1 cells. The protein expressed by the method is close to natural protein, has biological activity and is simple to operate. The qPCR and ELISA tests verify that the IZUMO2 protein can reduce the expression of inflammatory factors in RAW264.7 cells induced by LPS, and has a certain anti-inflammatory capacity. It is found through experiments that the IZUMO2 protein can promote the capacitation of boar sperm, and it is proved that the protein can be applied to the preparation of a reagent for promoting the capacitation of boar sperm.

The invention belongs to the technical field of forensic medicine and biological medicine, discloses a method for forensic medicine identification of corpses in water based on metagenomics markers and application, and aims to solve the problems that existing drowning diagnosis is insufficient in accuracy and the deduction of post-death submerging time (PMSI) is limited. The method comprises the following steps: collecting a corpse lung tissue in water and a water sample in a corresponding water area, and obtaining a microbial DNA sequence by adopting a metagenome sequencing technology; the method comprises the following steps: processing data through bioinformatics analysis (such as fastp quality control, host sequence removal by KneadData and Kraken2 species annotation), and selecting and screening species level microbial markers in combination with a random forest algorithm and Boruta characteristics; and respectively establishing a drowning diagnosis model and a PMSI inference model based on the screened markers, and verifying the performance of the models through indexes such as AUC and MAE. Complete microbial communities of bacteria, eukaryotes (including fungi), archaea and viruses in lung tissues of corpses in water are comprehensively analyzed for the first time, 17 bacterial markers and 9 eukaryote markers are screened out for drowning diagnosis (verification experiment bacterial model AUC = 1, the accuracy rate is 89.29%, eukaryote model AUC = 0.95, the accuracy rate is 87.5%), and 17 markers are screened out for PMSI inference (integrated model MAE = 0.66 days). According to the method, the species resolution reaches the species level, the method is not influenced by amplification bias, the method is suitable for different water area environments, and an efficient and objective forensic medicine tool is provided for identifying the cause of the dead body in water and deducing the submerged time after the dead body.

The invention discloses preparation and application of oligopeptide immune carrier protein, and belongs to the technical field of biology. The method comprises the following steps: fusing a gene sequence for coding oligopeptide and a gene sequence for coding ferritin through a chemical method by utilizing the characteristics that oligopeptide molecules are small in mass and ferritin is self-assembled to form a polymer, and then cloning the fused gene into a prokaryotic biological carrier for expression; the recombinant protein is purified by using an expression system which is not limited to prokaryotes such as escherichia coli and eukaryotes. The protein has the advantages of low preparation cost, strong immunogenicity and the like, and lays a foundation for obtaining a high-affinity anti-oligopeptide nano antibody.

The application belongs to the field of microorganism eukaryotes, and the strain preservation date is August 18, 2025, and the preservation number is CGMCC NO.35650. The vaccine is prepared by isolating and inactivating the Meyerozyma guiliardmi yeast ML001, the vaccine can significantly reduce the alcohol-induced ALT and AST levels in mice, reduce liver lipid accumulation, down-regulate fatty acid synthesis genes Fasn and Acly and up-regulate fatty acid oxidation genes Ppara and Cpt1a , thereby effectively inhibiting lipid synthesis and activating fatty acid oxidation, reducing alcoholic liver injury, and having no obvious toxicity to main organs such as heart, spleen, lung and kidney, and showing good safety and clinical transformation potential.

It has been established that one or more large double stranded DNA fragments (each 2,000 to 40,000 base pairs in size) can be captured and isolated from genomic DNA fragments using sequence specific PNA hybridization probes. Compositions and methods for enrichment of a multiplicity of long DNA sequences selected from the genome of any eukaryote are provided. Capture is performed using multiple PNA molecules with gamma-modified chiral backbones, comprising a mixture of neutral and positive chemical groups. Two or more PNA probes with covalently bound haptens, preferably biotin, target each DNA domain of interest for capture, isolation, and subsequent sequencing analysis of the multiplicity of enriched targets, including DNA methylation sequencing. The methods include enhancement of probe-DNA binding specificity through single strand binding proteins (SSB).

The invention relates to an AnaCas9 mutant as well as a gene editing system and application thereof, and relates to the technical field of biology. The AnaCas9 mutant is modified at a specific site, so that the gene editing activity of the AnaCas9 mutant is remarkably improved, and the AnaCas9 mutant can be widely applied to efficient gene editing of prokaryotes and eukaryotes and particularly can also realize efficient gene editing in mammalian cells (including human cells) and saccharomycetes.